





Alere™ i Influenza A&B

Molecular results in less than 15 minutes





> Faster Results

Outstanding Performance

Intuitive Design

Antimicrobial Stewardship

Ordering Information



Transforming near-patient testing

Unique isothermal amplification technology giving you molecular results, faster than ever before



Improving patient outcomes

Giving you the confidence to make effective clinical decisions sooner



Optimizing operational efficiency

- Enables prompt initiation of infection control measures
- Connected results direct to your network
- Facilitating effective patient management



Enabling effective Antimicrobial Stewardship

Molecular sensitivity in an actionable timeframe allows the prudent use of antibiotics and antivirals



A positive impact on your facility

Reliable near-patient testing reduces overall healthcare costs⁴



Confidence at the point of care

Intuitive and reliable, allowing you to respond quickly and accurately in any setting







> Faster Results

Outstanding Performance


Intuitive Design

Antimicrobial Stewardship

Ordering Information



Alere™ i utilizes unique isothermal nucleic acid amplification technology which does not require temperature cycling or a sample purification step







> Faster Results

Outstanding Performance


Intuitive Design

Antimicrobial Stewardship

Ordering Information



Alere™ i is significantly faster than other molecular methods and more accurate than conventional rapid testing giving you the confidence to make effective patient management decisions sooner





Faster Results

Outstanding Performance

Intuitive Design

Antimicrobial Stewardship

Ordering Information



"Alere™ i demonstrates impressive sensitivity for the detection of both influenza A and B in clinical respiratory specimens obtained from children and adults"³

Alere™ i Influenza A & B Performance vs. Culture¹

	Sensitivity	Specificity
Influenza A	97.9% (95% CI: 92.6%, 99.4%)	86.2% (95% CI: 82.8%, 89.0%)
Influenza B	92.5% (95% CI: 84.6%, 96.5%)	96.5% (95% CI: 94.5%, 97.8%)

Alere™ i Influenza A & B Performance vs. Culture¹ Discrepant result resolved by RT-PCR

	Sensitivity	Specificity
Influenza A	99.3% (95% Cl: 96.3%, 99.9%)	98.1% (95% CI: 96.3%, 99.9%)
Influenza B	97.8% (95% Cl: 92.3%, 99.4%)	99.6% (95% CI: 98.5%, 99.9%)

^{*}All specimens generating discrepant results between the **Alere** in Influenza A & B test and viral culture were tested using an FDA cleared RT-PCR assay to confirm influenza status. Performance of **Alere** in Influenza A & B when the results of PCR on discrepant samples are incorporated is presented in the table above.



Faster Results

Outstanding Performance

Intuitive Design

Antimicrobial Stewardship

Ordering Information



"A simple and easy to use molecular diagnostic test"2

- Sample type nasal swab
- Visual touchscreen no need for separate instructions
- Easy to use requires only minimal training



 Streamlined workflow connectivity can be provided to your network







Test Base

Sample Receiver

Transfer Cartridge



Simple

Easy to Use

In Any Setting



> Faster Results

Outstanding Performance


Intuitive Design

Antimicrobial Stewardship

Ordering Information




Easy to use with a simple touch screen









Simple

Easy to Use

In Any Setting



Suitable for use in any healthcare setting

Unique Technology

> Faster Results

Outstanding Performance

> Intuitive Design

Antimicrobial Stewardship

Ordering Information









Laboratory



Physician's Office


Alere[™] i products are Moderately Complex.

Simple

Easy to Use

In Any Setting





> Faster Results

Outstanding Performance


Intuitive Design

Antimicrobial Stewardship

Ordering Information





The **Test Target Treat**™ antimicrobial stewardship initiative from Alere empowers you to make targeted treatment decisions sooner with rapid diagnostics; reducing the inappropriate use of antibiotics and antivirals, and the spread of resistance.



Find out more at **TestTargetTreat.com**









Faster Results

Outstanding Performance

Intuitive Design

Antimicrobial Stewardship

Ordering Information



Visit Alere-i.com today

or contact us: Alere-i@alere.com

23046617	Alere™ i Instrument
23046618	Alere™ i Influenza A & B 24 Test Kit, CPT: 87502
23046619	Alere™ i Influenza A & B Control Swab Kit
EQ001001	Alere™ i Barcode Scanner
55115	Alere™ Universal Printer

References:

- 1. Alere™ i Influenza A & B Package Insert.
- 2. Bell, J. and Selvarangan, R. Evaluation of the Rapid Alere[®] i Influenza A & B Nucleic Acid Amplification Test Using Respiratory Specimens Collected in Viral Transport Medium. Poster presented at Clinical Virology Symposium. (2013) Children's Mercy Hospitals and Clinics, and University of Missouri, Kansas City School of Medicine, Kansas City, MO
- **3.** Bell, J. et al. (2013) Clinical Evaluation of the Alere^{*} i Influenza A & B Assay, a Point-of-Care Rapid Nucleic Acid Amplification Test for Detection of Influenza. Children's Mercy Hospitals and Clinics and University of Missouri Kansas City School of Medicine, Kansas City, MO. Veritas, P.A., Belton, TX. Nationwide Children's Hospital, Columbus, OH. New York Methodist Hospital, Brooklyn, NY. Ann & Robert Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL. Albany Medical College, Albany, NY. Wake Forest University Baptist Medical Center, Winston-Salem, NC.
- **4.** Bonner, A.B. et al. (2003) Impact of the Rapid Diagnosis of Influenza on Physician Decision-Making and Patient Management in the Pediatric Emergency Department: Results of a Randomized, Prospective, Controlled Trial. Pediatrics Vol. 112 No. 2.



